Show simple item record

dc.contributor.authorGiovannoni, Gen_US
dc.contributor.authorCohen, JAen_US
dc.contributor.authorColes, AJen_US
dc.contributor.authorHartung, H-Pen_US
dc.contributor.authorHavrdova, Een_US
dc.contributor.authorSelmaj, KWen_US
dc.contributor.authorMargolin, DHen_US
dc.contributor.authorLake, SLen_US
dc.contributor.authorKaup, SMen_US
dc.contributor.authorPanzara, MAen_US
dc.contributor.authorCompston, DASen_US
dc.contributor.authorInvestigators, CARE-MSIIen_US
dc.date.accessioned2016-10-31T08:39:19Z
dc.date.available2016-07-07en_US
dc.date.issued2016-11-08en_US
dc.date.submitted2016-09-29T11:21:01.034Z
dc.identifier.issn0028-3878en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/16162
dc.description.sponsorshipSupported by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals. Linda Kasten (Prometrika, LLC, Cambridge, MA) contributed to statistical analyses, which were funded by Sanofi Genzyme.en_US
dc.format.extent1985 - 1992en_US
dc.relation.ispartofNEUROLOGYen_US
dc.rightsThis is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
dc.titleAlemtuzumab improves preexisting disability in active relapsing-remitting MS patientsen_US
dc.typeArticle
dc.rights.holder© 2016 American Academy of Neurology
dc.identifier.doi10.1212/WNL.0000000000003319en_US
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000392233600009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue19en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume87en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record